期刊文献+

铜绿假单胞茵分布及耐药性分析 被引量:1

Distribution and drugresistance analy Si SO f pseudomonas aeruginosal
在线阅读 下载PDF
导出
摘要 目的:了解院内铜绿假单胞菌(PA)感染和耐药情况。方法:收集本院2008年8月~2009年7月分离的铜绿假单胞菌(PA)369株,按《全国检验技术操作规程》要求操作,用VITEK-32全自动细菌分析仪进行鉴定及药敏分析。结果:369株铜绿假单胞菌标本中痰液为最多占215株,其次为伤口分泌物占89株。铜绿假单胞菌分布以呼吸科最多占41.81%,其次为重症监护病房(1CU)占28.36%。药敏结果显示敏感率:分别为亚胺培南81.28%,美洛培南80.32%。头孢哌酮/舒巴坦80.51%,哌拉西林他唑巴坦78.65%,阿米卡星72.63%,头孢他啶68.88%。其余抗生素耐药情况比较严峻。结论:PA的耐药性已十分突出,对于PA感染应在药敏指导下用药,选择敏感性强的药物,避免耐药菌株的产生。 Obiective Toinvestigate the drngresistance tOP seudomonas aeruginosa. Metheds:Collected 369 strains of pseudomonas aeruginosa derived from the clinical infection from August 2008 to Jniy 2009 were analyzed according to the National Regulations On Clinical Laboratory Operations.The bacteriaand the drug resistance was analyzed were identified by the automated microbial analyzer VITEK-32oResuhs: Among 369 cases Of infected species(Pseudomonas aeruginosa isolated),sputum sample occupied the firSt place(n: 215),foUowed excreta(n= 89).Pseudomonas aernginosa was distributed inmost clinical departments, mostly in department of respiratory diseases (41.81%), followed m ICU(28.36%) o Drug sensitive mty test showed were as follows: imipenem(OPM81, 28%), mere(80.32%), cefoperazone/sulbactam(SCF)80.51%. piperacillin/tazobactam (TZP)78.65%.amikacin (AK) 72.63%.ceftazidime (CAZ)68, 88% .Drug sensitive rate Of Pseudomonasaeruginosat Oimlpenem, mem, peraciliin/- azobactam.drugresistancei Sausterityt Otheoddantibiotic. Conclusion The drugresistance Of PAi Shighlyprominent. Antimicrobialtreatment infectionshouldbeguidedbydrugsensitivitytest. choose ahigh-sensitivemedicineandavoid bacteria producedrug resistance
出处 《内蒙古中医药》 2010年第13期130-131,共2页 Inner Mongolia Journal of Traditional Chinese Medicine
关键词 铜绿假单胞菌 抗生素 耐药性分析 Pseudomonasaeruginosa antibactialagents drugresistanceanalysis
  • 相关文献

参考文献5

二级参考文献34

  • 1[1]Takenouchi T,Sakagawa E,Sugawara M.Detection of gyrA mutations among 335 Pseudomonas aeruginosa strains isolated in Japan and their susceptibilities to fluoroquinolones[J]. Antimicrob Agents Chemother, 1999, 43(2): 406-409.
  • 2[2]Mouneimne H, Jarlier V, Cambau E, et al. Type Ⅱ topoisomerase mutations in ciprofloxacin-resistance strains of Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother, 1999, 43(1): 62-66.
  • 3[3]Li XZ, Livermore DM, Nikaiclo H. Role of efflux pumps in intrinsic resistance of Pseudomonas aeruginosa resistance to tetracycline, chloramphenicol and norfloxacin[J]. Antimicrob Agents Chemother, 1994, 38: 1732-1741.
  • 4[4]Poole K, Bianco N, Neshat S, et al. Conservation of the multidrug resistance efflux gene oprM in Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother, 1997, 41: 853-856.
  • 5[5]Masuda N, Gotoh N, Ohya S, et al. Quantitative correlation between susceptibility and oprJ production in nfxB mutations of Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother, 1996, 40: 903-909.
  • 6[10]Cunha BA.Pseudomonas aeruginosa:resistance and therapy[J].Semin Respir Infect,2002,17(3):231 239.
  • 7Kolar M et al. J Chemother, 1999;11 (4): 260-265
  • 8Costerton JW. Int J Antimicrob Agents, 1999; 11(3-4) : 217-221
  • 9Consterton JW et al. Annu Rev Microbiol, 1981; 35: 299-324
  • 10Costerton JW et al. Science, 1999; 284(5418) :1318 -1322

共引文献638

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部